Intravitreal Injection of Bevacizumab for the Prevention of Postoperative Proliferative Vitreoretinopathy in High-Risk Patients Selected by Laser Flare Photometry
Ophthalmologica · 2023
DOI: 10.1159/000533750 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Ophthalmologica, 2023. Verfasst von Marie Gahon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative, Retinal Detachment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Introduction
To evaluate the effect of an intravitreal injection of bevacizumab at the time of rhegmatogenous retinal detachment (RRD) surgery, on postoperative proliferative vitreoretinopathy (PVR) in high-risk patients selected by laser flare photometry.
Methods
This single-center observational retrospective cohort study included 137 consecutive patients who underwent pars plana vitrectomy and gas tamponade for primary RRD with increased aqueous flare between July 2016 and June 2021. From June 2019, an intravitreal injection of bevacizumab was administered as an adjunct to RRD repair. Patients who underwent surgery before this time and who did not receive intravitreal bevacizumab served as controls. The main outcome was the rate of retinal redetachment due to PVR.
Results
The median flare value was 22.0 (16.5–36.5) pc/ms in the control group and 28.2 (19.7–41.0) pc/ms in the bevacizumab group (p = 0.063). Eyes treated with bevacizumab were more likely to have macula-off RRD (p = 0.003), grade B PVR (p = 0.038), and worse visual acuity (p = 0.004) than controls. The rate of PVR redetachment was significantly lower in the bevacizumab group (11.1%) than in the control (30.1%) (p = 0.012). This difference was more pronounced after adjusting for potential confounding factors (p = 0.005); the risk of developing PVR was 4.5-fold higher in controls (95% CI, 1.6–12.8). After adjustment, the final median visual acuity was also significantly higher in eyes treated with bevacizumab (p = 0.025).
Conclusion
This pilot study provides preliminary evidence that bevacizumab may reduce the risk of PVR-related recurrent RRD and improve visual outcomes in high-risk patients selected by laser flare photometry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
- Methodology, Promotion and Investigation Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France.
- School of Medicine, Université de Paris, Paris, France.
Zitieren
APA
Gahon, M., Luc, A., Zessler, A., Pastor, G., Angioi-Duprez, K., Thilly, N., Berrod, J. P., & Conart, J. B. (2023). Intravitreal Injection of Bevacizumab for the Prevention of Postoperative Proliferative Vitreoretinopathy in High-Risk Patients Selected by Laser Flare Photometry. Ophthalmologica. https://doi.org/10.1159/000533750
Vancouver
Gahon M, Luc A, Zessler A, Pastor G, Angioi-Duprez K, Thilly N, et al. Intravitreal Injection of Bevacizumab for the Prevention of Postoperative Proliferative Vitreoretinopathy in High-Risk Patients Selected by Laser Flare Photometry. Ophthalmologica. 2023. doi:10.1159/000533750
BibTeX
@article{Gahon2023,
author = {Gahon, Marie and Luc, Amandine and Zessler, Astrid and Pastor, Geoffrey and Angioi-Duprez, Karine and Thilly, Nathalie and Berrod, Jean-Paul and Conart, Jean-Baptiste},
title = {Intravitreal Injection of Bevacizumab for the Prevention of Postoperative Proliferative Vitreoretinopathy in High-Risk Patients Selected by Laser Flare Photometry},
journal = {Ophthalmologica},
year = {2023},
doi = {10.1159/000533750}
}
EUVIMED